Literature DB >> 28566531

SDHB mutation carriers with malignant pheochromocytoma respond better to CVD.

L Fishbein1, S Ben-Maimon2,3, S Keefe2,4, K Cengel5, D A Pryma6,7, A Loaiza-Bonilla2,4, D L Fraker8,9, K L Nathanson2,10,11, D L Cohen2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28566531     DOI： 10.1530/ERC-17-0086

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN： 1351-0088            Impact factor:   5.678


× No keyword cloud information.
  15 in total

1.  SDHB large deletions are associated with absence of MIBG uptake in metastatic lesions of malignant paragangliomas.

Authors:  Janaina Petenuci; Gustavo F C Fagundes; Anna Flavia F Benedetti; Augusto G Guimaraes; Ana Caroline F Afonso; Flavia T Mota; Aurea Luiza F Magalhães; George B Coura-Filho; Maria Claudia N Zerbini; Sheila Siqueira; Fabio L M Montenegro; Victor Srougi; Fabio Y Tanno; Jose Luis Chambo; Marcela S S Ferrari; Joao Evangelista Bezerra Neto; Maria Adelaide A Pereira; Ana Claudia Latronico; Maria Candida B V Fragoso; Berenice B Mendonca; Ana O Hoff; Madson Q Almeida
Journal:  Endocrine       Date:  2021-01-09       Impact factor: 3.633

2.  Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients.

Authors:  Julien Hadoux; Marie Terroir; Sophie Leboulleux; Frederic Deschamps; Abir Al Ghuzlan; Ségolène Hescot; Lambros Tselikas; Isabelle Borget; Caroline Caramella; Desirée Déandréis; Diane Goere; Thierry De Baere; Martin Schlumberger; Eric Baudin
Journal:  Horm Cancer       Date:  2017-07-26       Impact factor: 3.869

Review 3.  Head and Neck Paragangliomas: An Update on the Molecular Classification, State-of-the-Art Imaging, and Management Recommendations.

Authors:  Edward P Lin; Bennett B Chin; Lauren Fishbein; Toshio Moritani; Simone P Montoya; Shehanaz Ellika; Shawn Newlands
Journal:  Radiol Imaging Cancer       Date:  2022-05

4.  HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop.

Authors:  Patricia L M Dahia; Roderick Clifton-Bligh; Anne-Paule Gimenez-Roqueplo; Mercedes Robledo; Camilo Jimenez
Journal:  Endocr Relat Cancer       Date:  2020-08       Impact factor: 5.678

5.  Therapeutic Targeting of SDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid.

Authors:  Yang Liu; Ying Pang; Chunzhang Yang; Karel Pacak; Boqun Zhu; Ondrej Uher; Veronika Caisova; Thanh-Truc Huynh; David Taieb; Katerina Hadrava Vanova; Hans Kumar Ghayee; Jiri Neuzil; Mark Levine
Journal:  Clin Cancer Res       Date:  2020-03-09       Impact factor: 12.531

6.  High-specific-activity 131iodine-metaiodobenzylguanidine for therapy of unresectable pheochromocytoma and paraganglioma.

Authors:  Joseph S Dillon; David Bushnell; Douglas E Laux
Journal:  Future Oncol       Date:  2021-01-28       Impact factor: 3.404

Review 7.  New Directions in Treatment of Metastatic or Advanced Pheochromocytomas and Sympathetic Paragangliomas: an American, Contemporary, Pragmatic Approach.

Authors:  Camilo Jimenez; Guofan Xu; Jeena Varghese; Paul H Graham; Matthew T Campbell; Yang Lu
Journal:  Curr Oncol Rep       Date:  2022-01-21       Impact factor: 5.075

Review 8.  Advances in adrenal tumors 2018.

Authors:  J Crona; F Beuschlein; K Pacak; B Skogseid
Journal:  Endocr Relat Cancer       Date:  2018-07       Impact factor: 5.678

9.  Mutational profile and genotype/phenotype correlation of non-familial pheochromocytoma and paraganglioma.

Authors:  Shatha Albattal; Meshael Alswailem; Yosra Moria; Hindi Al-Hindi; Majed Dasouki; Mohamed Abouelhoda; Hala Aba Alkhail; Entissar Alsuhaibani; Ali S Alzahrani
Journal:  Oncotarget       Date:  2019-10-15

10.  Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.

Authors:  Heather Wachtel; Troy Hutchens; Ezra Baraban; Lauren E Schwartz; Kathleen Montone; Zubair Baloch; Virginia LiVolsi; Lauren Krumeich; Douglas L Fraker; Katherine L Nathanson; Debbie L Cohen; Lauren Fishbein
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.